Patricia Díaz-Gimeno is one of the Spanish scientists who has written about the current state of assisted reproduction in Spain. Several years ago, her doctoral thesis led her to discover the intricacies of endometrial receptivity, and her conclusions resulted in a test that is now used internationally in a large number of assisted reproduction treatments.
Currently, Dr. Díaz-Gimeno is pursuing her career in the IVI Foundation / La Fe Health Research Institute and was recently awarded a Miguel Servet Scholarship. She receives this recognition "as a golden opportunity in terms of resources to be able to advance in endometrial dysfunction”.
We talked to her about the future of science and, while she is optimistic about the idea that "genomics and new technologies will lead us to a more precise and personalized medicine", she wants to take the opportunity to highlight the role that science should play. In the words of the researcher, "it is essential to value scientific discoveries so that we can improve people's lives, to
promote science for the benefit of society".
What is the line of research that you are developing and that we as citizens are fortunate to have as a Miguel Servet?
The name of the research group I direct is Genomic and Systems Reproductive Medicine, and the specific line of research is Precision Medicine of Endometrial Implantation Failure. As the name suggests, we are in search of a therapy that provides a solution for those women who, due to endometrial problems, cannot achieve embryo implantation after assisted reproduction treatment.
Since you started your doctoral thesis, the endometrium has been an important part of your career. Which advances have been the most relevant in this field?
The quest to improve the diagnosis and treatment of unexplained infertility has been one of my research goals since I became a scientist. When there is no cause indicating reproductive failure in an infertile patient, it is usually attributed to problems in the endometrium, which must be a 5-star hotel for the embryo. The difference between the early days of my research and the present is that we now have much more experience in the use of artificial intelligence algorithms. These algorithms, when combined with genomic data, can predict the molecular state of the patient's endometrium which allows us to advance more quickly in improving diagnosis and potential treatments.
What does it mean to have a Miguel Servet contract in your scientific career?
A great deal of responsibility and pride. For a scientist, this contract not only represents recognition our work, but also the possibility of materializing results with all that we have learned over the last 14 years. It is the opportunity to design a diagnostic method that will help women and couples to achieve childbearing.
What do you as a scientist ask of science?
More flexibility and what all researchers want: to improve their infrastructure and procedures. Most importantly, we must place value on scientific discoveries so that they can improve people's lives.
We urgently need to promote the value of science for the benefit of society. As a self-reinforcing cycle, we need to set it in motion and accelerate